Biogen Inc. (NASDAQ:BIIB) reported Q2 2017 earnings this Morning, coming in at $5.04 per share, beating Wall Street’s estimates of $4.50 per Share. Revenue for the quarter came in at $3.08 billion beating analyst estimates of $2.81 billion
Analyst Coverage For Biogen Inc. (NASDAQ:BIIB)
These are 11 Hold Ratings, 12 Buy Ratings, 1 Strong Buy Rating .
The current consensus rating for Biogen Inc. (NASDAQ:BIIB) is Buy (Score: 2.58) with a consensus target price of $327.76 , a potential (15.13% upside)Recent Insider Trading for Biogen Inc. (NASDAQ:BIIB)
- On 7/19/2017 Susan H Alexander, EVP, sold 7,758 with an average share price of $285.00 per share and the total transaction amounting to $2,211,030.00.
- On 6/9/2017 Brian S Posner, Director, sold 1,084 with an average share price of $256.31 per share and the total transaction amounting to $277,840.04.
- On 5/1/2017 Michel Vounatsos, CEO, bought 1,402 with an average share price of $271.35 per share and the total transaction amounting to $380,432.70.
- On 4/27/2017 Alexander J. Denner, Director, bought 73,858 with an average share price of $278.50 per share and the total transaction amounting to $20,569,453.00.
- On 4/25/2017 Paul J Clancy, VP, sold 9,892 with an average share price of $290.00 per share and the total transaction amounting to $2,868,680.00.
- On 4/3/2017 Alfred Sandrock, CMO, sold 1,981 with an average share price of $274.08 per share and the total transaction amounting to $542,952.48.
Recent Trading for Biogen Inc. (NASDAQ:BIIB) Shares of Biogen Inc. closed the previous trading session at 286.27 up +1.57 0.55% with 1,476,166 shares trading hands.